Publications

Zanidatamab

Categories
Search
Zanidatamab
October 23, 2023
ESMO
Zanidatamab (ZW25), a HER2-Targeted Bispecific Antibody, in Combination With Chemotherapy and Tislelizumab in Patients With Advanced HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma: Updated Results From a Phase 1b/2 Study
Keun-Wook Lee, et al.
Zanidatamab
June 2, 2023
ASCO
Results from the Pivotal Phase 2b HERIZON-BTC-01 Study: Zanidatamab in Previously-treated HER2-amplified Biliary Tract Cancer (BTC)
Pant et al.
Zanidatamab
June 4, 2023
ASCO
Zanidatamab, a HER2-targeted Bispecific Antibody, in Combination With Docetaxel as First-line Therapy for Patients With Advanced HER2-positive Breast Cancer: Updated Results From a Phase 1b/2 Study
Wang et al.
Zanidatamab
June 2, 2023
Lancet Oncology
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
Harding et al.
Zanidatamab
April 18, 2023
AACR
ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in a Phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers
Shpektor et al.
Zanidatamab
March 13, 2023
Nature Communications
An anti-HER2 biparatopic antibody that induces unique HER2 clustering and complement-dependent cytotoxicity
Weisser et al.
Zanidatamab
January 19, 2023 - January 21, 2023
ASCO GI
Zanidatamab + Chemotherapy as First line Treatment for HER2 expressing Metastatic Gastroesophageal Adenocarcinoma (mGEA)
Elimova et al.
Zanidatamab
December 6, 2022 - December 10, 2022
SABCS
Antitumor Activity of Zanidatamab with Palbociclib and Fulvestrant in HER2+ Hormone-Receptor Positive (HR+) Metastatic Breast Cancer
Escrivá-de-Romani et al.
Zanidatamab
December 1, 2022
Lancet Oncology
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study
Meric-Bernstam et al.
Zanidatamab
August 24, 2022
Future Medicine
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma
Zanidatamab
June 30, 2022
ESMO World GI Congress
HERIZON-GEA-01: A Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in First-line Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced/metastatic Gastroesophageal Adenocarcinoma (GEA)
Tabernero et al.
Zanidatamab
June 6, 2022
ASCO
Zanidatamab, a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy for patients with advanced HER2-positive breast cancer: Preliminary results from a Phase 1b/2 study